• Explore /
  • Poster
  • / ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.

ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.

Abstract Poster

Authors

null

Peter Wojciech Szlosarek

St Bartholomew's Hospital, London, United Kingdom

Peter Wojciech Szlosarek , Paul Baas , Giovanni Luca Ceresoli , Dean Anthony Fennell , David Gilligan , Amanda Johnston , Phuong Lee , Aaron Scott Mansfield , Luke Nolan , Anna K. Nowak , Jeremy P. C. Steele , Paul Taylor , Anne S. Tsao , Marjorie Glass Zauderer , John S. Bomalaski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT02709512

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS8582)

DOI

10.1200/JCO.2017.35.15_suppl.TPS8582

Abstract #

TPS8582

Poster Bd #

314b

Abstract Disclosures

Similar Posters

First Author: Anne S. Tsao

First Author: Wieneke A. Buikhuisen

First Author: Arkadiusz Z. Dudek

First Author: Melissa Phillips